Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegadricase - 3SBio/Selecta Biosciences

Drug Profile

Pegadricase - 3SBio/Selecta Biosciences

Alternative Names: Pegsitacase; Pegsiticase; SEL 037; SSS11; Uricase-PEG 20

Latest Information Update: 22 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Phoenix Pharmacologics
  • Developer 3SBio; Selecta Biosciences
  • Class Enzymes; Oxidoreductases; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Urate oxidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tumour lysis syndrome; Lesch-Nyhan syndrome; Gout
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gout
  • Phase I/II Tumour lysis syndrome

Most Recent Events

  • 09 Aug 2019 Shenyang Sunshine Pharmaceutical plans a phase I pharmacokinetic trial in Chinese healthy volunteers in China in August 2019 (NCT04047394)
  • 01 Jan 2019 Selecta Biosciences completes a phase II trial in Gout in USA (IV) (NCT02959918)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top